Key result
VEGF-loaded hybrid pericardium enhances endothelialization while reducing platelet adhesion and calcification in rats.
Why the study?
Glutaraldehyde-fixed pericardium used for heart valve replacement lacks endothelialization, contributing to calcification and structural deterioration, especially in young patients where valve longevity is critical.
Does vascular endothelial growth factor-loaded elastin-hydrogel modification improve endothelialization and reduce calcification of bioprosthetic heart valves in preclinical models?
Does vascular endothelial growth factor-loaded elastin-hydrogel modification improve endothelialization and reduce calcification of bioprosthetic heart valves in preclinical models?
VEGF-loaded elastin-hydrogel modification of pericardial tissue improves endothelialization and reduces calcification in preclinical models, suggesting a promising approach for more durable bioprosthetic heart valves.
May enhance endothelialization on bioprosthetic valves; hypothesis-generating for reduced calcification, needs in vivo validation before practice change.
Glutaraldehyde-fixed pericardium is widely used to replace human heart valves. The lack of endothelialization contributes to calcification and structural-valve deterioration, which is particularly significant in young patients where valve longevity is crucial. This current study demonstrates an optimized approach to improve endothelialization of glutaraldehyde-fixed pericardium. Vascular endothelial growth factor-loaded elastin-hydrogel-hybrid pericardium was developed by the crosslinking reaction between the amine groups of soluble elastin and hexamethylene diisocyanate. The elastin solution can penetrate the space of the pericardium. Vascular endothelial growth factor was loaded into the elastin hydrogel, which was hybridized with pericardium via in situ polymerization. We investigated the adhesion and growth potential of human umbilical vein endothelial cells on pericardia, platelet adhesion, and calcification via an in vivo rat model of subdermal implantation. Vascular endothelial growth factor-loaded elastin-hydrogel-hybrid pericardium showed improved human umbilical vein endothelial cell adhesion and proliferation, less platelet adhesion, and less calcification. Thus, the vascular endothelial growth factor-loaded elastin-hydrogel-hybrid pericardium is a promising approach to obtain valve bioprostheses for clinical applications with increased endothelialization, antithrombotic and anti-calcification potential.
No takes yet. Share an insight, caveat, or question.
Lei et al. (2019) studied Bioprosthetic heart valve replacement. Vascular endothelial growth factor-loaded elastin-hydrogel-hybrid pericardium vs. Glutaraldehyde-fixed pericardium was evaluated on Endothelial cell adhesion and proliferation, platelet adhesion, and calcification. Vascular endothelial growth factor-loaded elastin-hydrogel-hybrid pericardium improved endothelial cell adhesion and proliferation, with less platelet adhesion and calcification in a rat model.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: